OR1L3

Across TCGA pan-cancer cohorts, OR1L3 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of OR1L3’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where OR1L3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types OR1L3 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

PRAD and COAD are the cancer types where OR1L3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in OR1L3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.019	.043	2	view →
COAD	All	II,III,IV	−0.012	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

OR1L3–PRAD

Open the PRAD breakdown →